NKTX: Nkarta, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 122.40
Enterprise Value ($M) -229.50
Book Value ($M) 378.81
Book Value / Share 5.34
Price / Book 0.32
NCAV ($M) 260.10
NCAV / Share 3.67
Price / NCAV 0.47

Profitability (mra)
Return on Invested Capital (ROIC) -0.24
Return on Assets (ROA) -0.19
Return on Equity (ROE) -0.23

Liquidity (mrq)
Quick Ratio 27.29
Current Ratio 27.29

Balance Sheet (mrq) ($M)
Current Assets 351.90
Assets 470.61
Liabilities 91.80
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -128.19
Net Income -108.79

Cash Flow Statement (mra) ($M)
Cash From Operations -99.70
Cash from Investing -129.56
Cash from Financing 226.08

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Commodore Capital Lp 0.50 -92.45
02-12 13G/A Adage Capital Partners Gp, L.l.c. 0.00 -100.00
02-12 13D/A LSP 6 Holding C.V. 4.00 0.00
01-27 13G Tang Capital Management Llc 9.90
12-13 13G Citadel Advisors Llc 5.40
11-14 13G/A Flynn James E 3.05 -36.62
11-12 13G/A Adage Capital Management, L.P. 5.10
11-08 13G BlackRock, Inc. 6.00 0.00
10-25 13G/A Boxer Capital Management, LLC 4.90

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2025-03-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-15 201,901 623,635 32.37
2025-05-14 65,958 258,698 25.50
2025-05-13 125,697 378,667 33.19

(click for more detail)

Similar Companies
MYGN – Myriad Genetics, Inc. NBIX – Neurocrine Biosciences, Inc.
NEOG – Neogen Corporation NMRA – Neumora Therapeutics, Inc.
NUVL – Nuvalent, Inc.


Financial data and stock pages provided by
Fintel.io